A detailed history of California State Teachers Retirement System transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 56,454 shares of VERV stock, worth $303,722. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,454
Previous 58,193 2.99%
Holding current value
$303,722
Previous $283,000 3.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.4 - $7.86 $7,651 - $13,668
-1,739 Reduced 2.99%
56,454 $273,000
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $21,696 - $58,296
4,558 Added 8.5%
58,193 $283,000
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $42,288 - $70,259
-3,912 Reduced 6.8%
53,635 $712,000
Q4 2023

Feb 13, 2024

BUY
$8.84 - $18.7 $71,215 - $150,647
8,056 Added 16.28%
57,547 $802,000
Q3 2023

Nov 14, 2023

SELL
$11.42 - $20.82 $31,336 - $57,130
-2,744 Reduced 5.25%
49,491 $656,000
Q2 2023

Aug 21, 2023

BUY
$13.34 - $19.9 $67,833 - $101,191
5,085 Added 10.78%
52,235 $979,000
Q1 2023

May 09, 2023

SELL
$14.3 - $24.01 $2,273 - $3,817
-159 Reduced 0.34%
47,150 $679,000
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $29,398 - $67,032
1,647 Added 3.61%
47,309 $915,000
Q3 2022

Nov 18, 2022

BUY
$15.63 - $41.49 $211,630 - $561,774
13,540 Added 42.15%
45,662 $1.57 Million
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $23,728 - $49,352
2,130 Added 7.1%
32,122 $491,000
Q1 2022

May 16, 2022

BUY
$20.92 - $39.36 $152,067 - $286,107
7,269 Added 31.99%
29,992 $684,000
Q4 2021

Feb 15, 2022

BUY
$31.94 - $54.82 $453,068 - $777,621
14,185 Added 166.14%
22,723 $838,000
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $392,748 - $631,726
8,538 New
8,538 $401,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $322M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.